Search

Your search keyword '"Garcia Tsao G"' showing total 519 results

Search Constraints

Start Over You searched for: Author "Garcia Tsao G" Remove constraint Author: "Garcia Tsao G"
519 results on '"Garcia Tsao G"'

Search Results

2. Early trends in cystatin c and outcomes in patients with cirrhosis and acute kidney injury

5. List of Contributors

6. Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection

7. Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis : A pilot study (RIFA-AH)

8. Corrigendum to ‘Baveno VII – Renewing consensus in portal hypertension’ [J Hepatol (2022) 959-974, (S0168827821022996), (10.1016/j.jhep.2021.12.022)]

12. Sepsis in cirrhosis: report on the 7th meeting of the international ascites club

15. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia

17. Under-dilated TIPS Associate With Efficacy and Reduced Encephalopathy in a Prospective, Non-randomized Study of Patients With Cirrhosis

18. Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine

20. Ordinal Outcomes Are Superior to Binary Outcomes for Designing and Evaluating Clinical Trials in Compensated Cirrhosis

21. Impatto dei farmaci anti virali ad azione diretta sulla cura dei pazienti con epatite C: un approccio di value-based medicine

22. Applicazione della value-based medicine nella valutazione della cura dei pazienti affetti da epatite

24. AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)

27. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis

28. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis

29. 13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH

30. Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis

31. A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension

32. Thrombelastography-Guided Blood Product Use Before Invasive Procedures in Cirrhosis With Severe Coagulopathy: A Randomized, Controlled Trial

33. Beta‐blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation

34. Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes

35. Hyponatremia and Hepatorenal Syndrome

38. In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation

39. A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis

40. Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatients

41. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) predicts 30-day mortality in admitted cirrhotic patients

47. In-Hospital Mortality Related to Hepatic Encephalopathy is Independent of Acute-On-Chronic Liver Failure and Varies Significantly across North America: Nacseld Experience

48. Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival

Catalog

Books, media, physical & digital resources